This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Suzuki, E. Articles by Ling, L. E. Search for Related Content PubMed PubMed Citation Articles by Suzuki, E. Articles by Ling, L. E.

A Novel Small-Molecule Inhibitor of Transforming Growth Factor ß Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection

¹ Thoracic Oncology Research Laboratory, University of Pennsylvania, Philadelphia, Pennsylvania and ² Oncology Cell Signaling, Biogen Idec, Cambridge, Massachusetts

Requests for reprints: Steven M. Albelda, Thoracic Oncology Research Laboratory, University of Pennsylvania, BRB II/III, 421 Curie Boulevard, Philadelphia, PA 19104. Phone: 215-573-9969; Fax: 215-573-4469; E-mail: albelda{at}mail.med.upenn.edu.

Malignant mesothelioma is an aggressive and lethal pleural cancer that overexpresses transforming growth factor ß (TGFß). We investigated the efficacy of a novel small-molecule TGFß type I receptor (ALK5) kinase inhibitor, SM16, in the AB12 syngeneic model of malignant mesothelioma. SM16 inhibited TGFß signaling seen as decreased phosphorylated Smad2/3 levels in cultured AB12 cells (IC₅₀, 200 nmol/L). SM16 penetrated tumor cells in vivo, suppressing tumor phosphorylated Smad2/3 levels for at least 3 h following treatment of tumor-bearing mice with a single i.p. bolus of 20 mg/kg SM16. The growth of established AB12 tumors was significantly inhibited by 5 mg/kg/d SM16 (P < 0.001) delivered via s.c. miniosmotic pumps over 28 days. The efficacy of SM16 was a result of a CD8⁺ antitumor response because (a) the antitumor effects were markedly diminished in severe combined immunodeficient mice and (b) CD8⁺ T cells isolated from spleens of mice treated with SM16 showed strong antitumor cytolytic effects whereas CD8⁺ T cells isolated from spleens of tumor-bearing mice treated with control vehicle showed minimal activity. Treatment of mice bearing large tumors with 5 mg/kg/d SM16 after debulking surgery reduced the extent of tumor recurrence from 80% to <20% (P < 0.05). SM16 was also highly effective in blocking and regressing tumors when given p.o. at doses of 0.45 or 0.65 g/kg in mouse chow. Thus, SM16 shows potent activity against established AB12 malignant mesothelioma tumors using an immune-mediated mechanism and can significantly prevent tumor recurrence after resection of bulky AB12 malignant mesothelioma tumors. These data suggest that ALK5 inhibitors, such as SM16, offer significant potential for the treatment of malignant mesothelioma and possibly other cancers. [Cancer Res 2007;67(5):2351–9]

This article has been cited by other articles:

				A. Wallace, V. Kapoor, J. Sun, P. Mrass, W. Weninger, D. F. Heitjan, C. June, L. R. Kaiser, L. E. Ling, and S. M. Albelda Transforming Growth Factor-{beta} Receptor Blockade Augments the Effectiveness of Adoptive T-Cell Therapy of Established Solid Cancers Clin. Cancer Res., June 15, 2008; 14(12): 3966 - 3974. [Abstract] [Full Text] [PDF]

				J.-S. Nam, M. Terabe, M. Mamura, M.-J. Kang, H. Chae, C. Stuelten, E. Kohn, B. Tang, H. Sabzevari, M. R. Anver, et al. An Anti-Transforming Growth Factor {beta} Antibody Suppresses Metastasis via Cooperative Effects on Multiple Cell Compartments Cancer Res., May 15, 2008; 68(10): 3835 - 3843. [Abstract] [Full Text] [PDF]

				J.-S. Nam, M. Terabe, M.-J. Kang, H. Chae, N. Voong, Y.-a. Yang, A. Laurence, A. Michalowska, M. Mamura, S. Lonning, et al. Transforming Growth Factor {beta} Subverts the Immune System into Directly Promoting Tumor Growth through Interleukin-17 Cancer Res., May 15, 2008; 68(10): 3915 - 3923. [Abstract] [Full Text] [PDF]

				S. H. Wrzesinski, Y. Y. Wan, and R. A. Flavell Transforming Growth Factor-{beta} and the Immune Response: Implications for Anticancer Therapy Clin. Cancer Res., September 15, 2007; 13(18): 5262 - 5270. [Abstract] [Full Text] [PDF]